Home > Insider Trading > Filing (0001209191-19-007570)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1445283	Proteostasis Therapeutics Inc.	PTI	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1688268	S. Geoffrey Gilmartin	C/O Proteostasis Therapeutics, Inc. 80 Guest Street, Suite 500 Boston MA 02135	Chief Development Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-02-01	24,100	$0.00	24,100	No	4	M	Direct
Common Stock	Disposition	2019-02-04	9,189	$2.99	14,911	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2019-02-01	24,100	$0.00	24,100	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one share of PTI common stock.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and were made in order to pay the tax liability arising from the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.96 to $3.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The restricted stock units vested in full on February 1, 2019.